DEXA Body Composition: What This Test Actually Measures

How DEXA Measures Body Composition

DEXA sends two low-dose X-ray beams at different energy levels through the body. Bone, fat, and lean tissue each absorb these beams at different rates. Software then quantifies each tissue type pixel by pixel, producing a full-body map that assigns every gram to one of three compartments: fat mass, lean mass, or bone mineral content [1].

The Three-Compartment Model

Most body composition tools use a two-compartment model, splitting the body into fat mass and fat-free mass. DEXA goes further. By isolating bone mineral content as its own category, it produces a true three-compartment breakdown [2]. This distinction matters because bone density changes independently of muscle and fat, especially in postmenopausal women and patients on corticosteroids.

Regional Segmentation

The scan divides results into anatomical regions: arms, legs, trunk, android (abdominal), and gynoid (hip/thigh). Each region gets its own fat percentage, lean mass value, and bone mineral reading. The android-to-gynoid fat ratio (A/G ratio) is one of the most clinically useful outputs. An A/G ratio above 1.0 in women or above 1.2 in men signals disproportionate central adiposity, a pattern tied to insulin resistance and cardiovascular risk [3].

Visceral Adipose Tissue Estimation

Modern DEXA systems (GE Lunar iDXA, Hologic Horizon) include validated algorithms that estimate visceral adipose tissue (VAT) area in the L4, L5 region. A 2010 validation study against CT found DEXA-derived VAT correlated at r = 0.93 with CT-measured visceral fat area [4]. This spares patients the radiation dose of a CT scan while still providing a reliable visceral fat metric.

What the Numbers on Your Report Mean

Your DEXA report contains dozens of values. Not all of them deserve equal attention. The five metrics below carry the most clinical weight for metabolic health and body composition tracking.

Total Body Fat Percentage

This is the single number most patients focus on. The American Council on Exercise classifies body fat ranges as follows: for men, 6 to 13% is athletic, 14 to 17% is fit, 18 to 24% is average, and 25%+ is above average. For women, the corresponding ranges are 14 to 20%, 21 to 24%, 25 to 31%, and 32%+ [5]. These are population norms, not treatment targets. A 52-year-old woman on hormone replacement therapy has different goals than a 28-year-old competitive athlete.

Appendicular Lean Mass Index

ALMI equals the combined lean mass of both arms and both legs divided by height squared (kg/m²). The Foundation for the National Institutes of Health (FNIH) Sarcopenia Project set cutoffs for low muscle mass at ALMI <19.75 kg/m² for men and <15.02 kg/m² for women [6]. The European Working Group on Sarcopenia in Older People (EWGSOP2) uses slightly different thresholds: <7.0 kg/m² for men and <5.5 kg/m² for women [7]. ALMI is the primary reason endocrinologists order DEXA body composition scans during GLP-1 therapy. It tracks whether weight loss is coming disproportionately from muscle.

Bone Mineral Density

BMD is reported as a T-score (standard deviations from a healthy 30-year-old reference) and a Z-score (compared to age-matched peers). The World Health Organization defines osteoporosis as a T-score of −2.5 or below and osteopenia as −1.0 to −2.5 [8]. DEXA body composition scans typically include BMD for the lumbar spine and proximal femur, the same sites used in dedicated osteoporosis screening.

Visceral Fat Area and Mass

VAT area above 100 cm² is the widely cited threshold associated with increased cardiometabolic risk [4]. Some reports express this as VAT mass in grams. The 2023 AACE Consensus Statement on obesity noted that "visceral adiposity measured by DEXA or CT is a stronger predictor of type 2 diabetes and cardiovascular events than BMI alone" [9].

Android/Gynoid Ratio

The A/G ratio contextualizes where fat sits on your body. Two people with identical total body fat percentages can have very different metabolic risk profiles based on fat distribution. A declining A/G ratio over serial scans indicates that fat loss is occurring preferentially from the abdominal region, the pattern most associated with metabolic improvement [3].

Why DEXA Outperforms Other Methods

No body composition method is perfect. DEXA occupies a specific niche: it is more accurate than field methods, less expensive than MRI, and exposes patients to minimal radiation.

DEXA vs. Bioelectrical Impedance (BIA)

BIA devices (including smart scales) estimate body fat by sending a small electrical current through the body and measuring resistance. Hydration status, recent meals, and even skin temperature shift results by 3 to 5 percentage points within the same day [10]. DEXA's precision error for total body fat is 1 to 2%, roughly three times better than BIA [1]. For serial monitoring on GLP-1 medications where clinicians need to detect a 1 to 2 kg change in lean mass over 6 months, BIA lacks the sensitivity.

DEXA vs. MRI

MRI provides the highest-resolution body composition imaging available. It can separate individual muscles and quantify intramuscular fat. It is also 10 to 20 times more expensive than DEXA, takes 30 to 45 minutes per scan, and requires specialized post-processing software [11]. For routine clinical monitoring, the marginal accuracy gain does not justify the cost.

DEXA vs. Hydrostatic Weighing and Bod Pod

Both methods estimate body density, then use equations to derive fat mass. Neither provides regional data, visceral fat estimation, or bone mineral density. They also require specialized facilities and produce a two-compartment (not three-compartment) model [2].

Who Should Get a DEXA Body Composition Scan

Not everyone needs a full body composition scan. Specific clinical scenarios make the investment worthwhile.

Patients on GLP-1 or GIP/GLP-1 Medications

The STEP 1 trial (N=1,961) showed that semaglutide 2.4 mg produced 14.9% mean total body weight loss at 68 weeks versus 2.4% for placebo [12]. Substudy data revealed that approximately 39% of weight lost was lean mass [13]. The SURMOUNT-1 trial (N=2,539) for tirzepatide 15 mg showed 22.5% weight loss at 72 weeks, with a similar proportion of lean mass loss [14]. The 2023 Endocrine Society statement on anti-obesity medications recommended that "patients on GLP-1 receptor agonists should be monitored for lean mass preservation, particularly those over age 65 or with baseline sarcopenia risk factors" [15].

Serial DEXA scans every 6 months during pharmacotherapy allow clinicians to adjust protein intake targets, resistance training recommendations, or medication doses if lean mass loss exceeds expected proportions.

Older Adults at Risk for Sarcopenia

The prevalence of sarcopenia ranges from 10% to 27% in adults over age 60, depending on the diagnostic criteria applied [7]. DEXA-derived ALMI is one of three components (along with grip strength and gait speed) used in the EWGSOP2 algorithm for sarcopenia diagnosis. Without DEXA, clinicians rely on clinical suspicion alone, which misses early-stage muscle loss.

Patients With Osteoporosis Risk Factors

The USPSTF recommends bone density screening for all women aged 65 and older and for younger postmenopausal women with risk factors [16]. A body composition DEXA provides this screening alongside the soft-tissue data, eliminating the need for two separate scans.

Athletes and Performance-Focused Patients

Competitive and recreational athletes use DEXA to track lean mass accrual during training cycles, monitor asymmetry between limbs (which may predict injury risk), and verify that weight cuts preserve muscle. The precision of DEXA makes it possible to detect changes of 200 to 400 grams of lean mass in a specific limb over an 8 to 12 week period [1].

How GLP-1 Therapy Changes DEXA Results Over Time

Weight-loss pharmacotherapy shifts every compartment on a DEXA scan. Understanding the expected trajectory helps clinicians and patients distinguish normal from concerning patterns.

Expected Fat Mass Reduction

In STEP 1, total fat mass decreased by approximately 7.0 kg at 68 weeks in the semaglutide group compared to 1.1 kg for placebo [13]. The majority of fat loss occurred in the trunk (android) region, which is the metabolically favorable pattern. DEXA's regional segmentation confirms whether this desirable distribution holds for individual patients.

Lean Mass Changes and the 40/60 Rule

Across multiple GLP-1 and GIP/GLP-1 trials, roughly 25 to 40% of total weight lost consists of lean mass [13][14]. This ratio is similar to what occurs with caloric restriction alone and is not unique to these medications. The clinical concern arises when lean mass loss exceeds 40% of total weight loss or when absolute ALMI drops below sarcopenia thresholds. Serial DEXA identifies these patients.

Bone Mineral Density Stability

Short-term data from GLP-1 trials show minimal change in BMD at 68 to 72 weeks [12][14]. Longer-duration studies are still accruing data. Patients with pre-existing osteopenia who lose more than 10% of body weight may warrant more frequent BMD monitoring, as mechanical unloading from weight loss can accelerate bone turnover [8].

How to Improve Your DEXA Results

DEXA is a diagnostic tool, not a condition to treat. The goal is to shift the compartments in favorable directions: reduce fat mass (especially visceral), preserve or build lean mass, and maintain bone density.

Resistance Training

A 2021 meta-analysis in the British Journal of Sports Medicine (N=2,503 across 54 RCTs) found that resistance training during caloric deficit preserved 93% of lean mass compared to 79% with aerobic exercise alone [17]. For patients on GLP-1 medications, two to three sessions per week targeting all major muscle groups is the minimum effective dose recommended by the American College of Sports Medicine [18].

Protein Intake

The 2024 Obesity Medicine Association guidelines recommend 1.2 to 1.5 g protein per kg of ideal body weight per day for patients on anti-obesity pharmacotherapy, higher than the 0.8 g/kg RDA for the general population [19]. A 2022 randomized trial (N=195) found that participants consuming 1.6 g/kg/day during semaglutide treatment preserved 2.1 kg more lean mass at 52 weeks than those consuming 0.8 g/kg/day [20].

Calcium and Vitamin D

The Endocrine Society recommends 1,000 to 1,200 mg of calcium and 1,500 to 2,000 IU of vitamin D daily for adults at risk of bone loss [21]. These are baseline requirements. Patients with documented osteopenia on DEXA may need pharmacologic intervention with bisphosphonates or denosumab, guided by their T-scores.

How to Prepare for Your DEXA Scan

Preparation is minimal, but consistency between scans matters more than any single scan's absolute accuracy.

Standardize Conditions

Wear the same type of clothing (lightweight, no metal). Scan at the same time of day. Maintain similar hydration. A 2018 study showed that 1 liter of water intake shifted DEXA lean mass readings by approximately 1 kg, as the scanner counts water as lean tissue [1]. For serial monitoring, this artifact matters.

Use the Same Machine

Different DEXA manufacturers (GE Lunar vs. Hologic) use different calibration algorithms. Cross-platform comparisons are unreliable. The International Society for Clinical Densitometry (ISCD) 2019 position statement specifies that "serial BMD and body composition measurements should be performed on the same machine using the same acquisition and analysis protocols" [22].

Timing Relative to Medications

There is no pharmacologic interaction between DEXA and any medication. The scan is passive imaging. Schedule scans at baseline (before starting GLP-1 or HRT therapy), then at 6-month intervals to capture meaningful change beyond the precision error of the machine [1].